MX9709112A - Combinacion para el tratamiento de parkinsonismo que contienen antagonistas selectivos de n-metil-d-aspartato. - Google Patents
Combinacion para el tratamiento de parkinsonismo que contienen antagonistas selectivos de n-metil-d-aspartato.Info
- Publication number
- MX9709112A MX9709112A MX9709112A MX9709112A MX9709112A MX 9709112 A MX9709112 A MX 9709112A MX 9709112 A MX9709112 A MX 9709112A MX 9709112 A MX9709112 A MX 9709112A MX 9709112 A MX9709112 A MX 9709112A
- Authority
- MX
- Mexico
- Prior art keywords
- parkinsonism
- combinations
- treatment
- selective nmda
- nmda antagonists
- Prior art date
Links
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 title 1
- 208000027089 Parkinsonian disease Diseases 0.000 title 1
- 206010034010 Parkinsonism Diseases 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000002964 excitative effect Effects 0.000 abstract 1
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 210000004129 prosencephalon Anatomy 0.000 abstract 1
- 239000011885 synergistic combination Substances 0.000 abstract 1
- 210000001103 thalamus Anatomy 0.000 abstract 1
- 210000002071 ventral thalamic nuclei Anatomy 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G10—MUSICAL INSTRUMENTS; ACOUSTICS
- G10H—ELECTROPHONIC MUSICAL INSTRUMENTS; INSTRUMENTS IN WHICH THE TONES ARE GENERATED BY ELECTROMECHANICAL MEANS OR ELECTRONIC GENERATORS, OR IN WHICH THE TONES ARE SYNTHESISED FROM A DATA STORE
- G10H5/00—Instruments in which the tones are generated by means of electronic generators
- G10H5/10—Instruments in which the tones are generated by means of electronic generators using generation of non-sinusoidal basic tones, e.g. saw-tooth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Multimedia (AREA)
- Acoustics & Sound (AREA)
- Physics & Mathematics (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Hydrogenated Pyridines (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
Abstract
Esta invencion se refiere a un método de tratamiento de la Enfermedad de Parkinson en el que se trata un mamífero que sufre la Enfermedad del Parkinson con una combinacion de un antagonista selectivo de NMDA del cerebro anterior y un compuesto que es capaz de aumentar la retroalimentacion excitadora desde el nucleo vetrolateral del tálamo al cortex; esta invencion también se refiere a composiciones farmacéuticas que contienen la combinacion sinérgica.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IB1995/000398 WO1996037226A2 (en) | 1995-05-26 | 1995-05-26 | Combinations for the treatment of parkinsonism containing selective nmda antagonists |
HU9601419A HUP9601419A3 (en) | 1995-05-26 | 1996-05-24 | Synergetic pharmaceutical compositions for treating parkinson-disease |
Publications (1)
Publication Number | Publication Date |
---|---|
MX9709112A true MX9709112A (es) | 1998-02-28 |
Family
ID=89994003
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX9709112A MX9709112A (es) | 1995-05-26 | 1995-05-26 | Combinacion para el tratamiento de parkinsonismo que contienen antagonistas selectivos de n-metil-d-aspartato. |
Country Status (26)
Country | Link |
---|---|
US (1) | US6258827B1 (es) |
EP (1) | EP0828513B1 (es) |
JP (1) | JPH11505828A (es) |
CN (1) | CN1159325A (es) |
AT (1) | ATE258067T1 (es) |
AU (1) | AU696258B2 (es) |
BR (1) | BR9602485A (es) |
CA (1) | CA2219911C (es) |
CO (1) | CO4700422A1 (es) |
CZ (1) | CZ283979B6 (es) |
DE (1) | DE69532482T2 (es) |
DK (1) | DK0828513T3 (es) |
ES (1) | ES2211904T3 (es) |
FI (1) | FI974323A (es) |
HU (1) | HUP9601419A3 (es) |
IL (1) | IL118328A (es) |
MX (1) | MX9709112A (es) |
NO (1) | NO962130L (es) |
NZ (1) | NZ286656A (es) |
PL (1) | PL314413A1 (es) |
PT (1) | PT828513E (es) |
RU (1) | RU2176145C2 (es) |
SG (1) | SG45479A1 (es) |
TR (1) | TR199600436A2 (es) |
TW (1) | TW470740B (es) |
WO (1) | WO1996037226A2 (es) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2321190B (en) * | 1997-01-16 | 2000-09-20 | Britannia Pharmaceuticals Ltd | Pharmaceutical composition |
HUP0004900A3 (en) * | 1997-10-24 | 2002-03-28 | Warner Lambert Co | Pharmaceutical compositions for treating disease-related or drug-induced dyskinesias containing piperidine derivatives as nmda receptor antagonist as active ingredient |
US6432976B1 (en) | 1999-10-29 | 2002-08-13 | Merck & Co., Inc. | 8-aza-bicyclo[3.2.1]octane NMDA/NR2B antagonists |
US6495561B2 (en) | 1999-10-29 | 2002-12-17 | Merck & Co., Inc. | 2-cyclohexyl imidazopyridine NMDA/NR2B antagonists |
US6362196B1 (en) | 1999-10-29 | 2002-03-26 | Merck & Co., Inc. | Method to treat pain utilizing benzimidazole NMDA/NR2B antagonists |
US6291499B1 (en) | 1999-10-29 | 2001-09-18 | Merck & Co., Inc. | 2-cyclohexyl benzimidazole NMDA/NR2B antagonists |
US6316474B1 (en) | 1999-10-29 | 2001-11-13 | Merck & Co., Inc. | 2-benzyl and 2-heteroaryl benzimidazole NMDA/NR2B antagonists |
US6380205B1 (en) | 1999-10-29 | 2002-04-30 | Merck & Co., Inc. | 2-cyclohexyl quinazoline NMDA/NR2B antagonists |
US6489477B1 (en) | 1999-10-29 | 2002-12-03 | Merck & Co., Inc. | 2-aza-bicyclo[2.2.2]octane NMDA/NR2B antigonists |
US6369076B1 (en) | 1999-10-29 | 2002-04-09 | Merck & Co. Inc. | 5-benzyl-octahydroindole and 6-benzyl-decahydroquinoline NMDA/NR2B antagonists |
US6476041B1 (en) | 1999-10-29 | 2002-11-05 | Merck & Co., Inc. | 1,4 substituted piperidinyl NMDA/NR2B antagonists |
EP1186303A3 (en) * | 2000-09-06 | 2003-12-10 | Pfizer Products Inc. | Pharmaceutical combinations, for the treatment of stroke and traumatic brain injury, containing a neutrophil inhibiting factor and an selective NMDA-NR2B receptor antagonist |
ATE324371T1 (de) | 2001-02-23 | 2006-05-15 | Merck & Co Inc | N-substituierte heterocyclische nichtaryl- nmda/nr2b-antagonisten |
US20020165246A1 (en) * | 2001-03-05 | 2002-11-07 | Andrew Holman | Administration of sleep restorative agents |
EP1436258A4 (en) * | 2001-03-08 | 2005-03-23 | Univ Emory | ANTAGONISTS OF THE NMDA RECEPTOR DEPENDENT OF PH |
EP1390034A4 (en) | 2001-04-03 | 2005-07-13 | Merck & Co Inc | NMDA / NR2B NONARYL-HETEROCYCLO AMIDYL N-SUBSTITUTE ANTAGONISTS |
US20030045449A1 (en) * | 2001-08-15 | 2003-03-06 | Pfizer, Inc. | Pharmaceutical combinations for the treatment of neurodegenerative diseases |
DE10142176A1 (de) * | 2001-08-29 | 2003-03-27 | Eucro Europe Contract Res Gmbh | Verwendung einer Kombination aus ß-adrenergen Agonisten und NDMA-Antagonisten |
WO2003062235A1 (en) * | 2002-01-17 | 2003-07-31 | Eli Lilly And Company | Modulators of acetylcholine receptors |
US6743921B2 (en) * | 2002-01-24 | 2004-06-01 | Dsm Catalytica Pharmaceuticals, Inc. | Process for the preparation of nonracemic syn-1-(4-hydroxy-phenyl)-2-(4-hydroxy-4-phenyl-piperidin-1-yl)-1-propanol compounds |
ES2297233T3 (es) * | 2002-10-08 | 2008-05-01 | Allergan, Inc. | Uso de brimonidina en el tratamiento de demencia y enfermedad de parkinson. |
AR044007A1 (es) | 2003-04-11 | 2005-08-24 | Newron Pharmaceuticals Inc | Metodos para el tratamiento de la enfermedad de parkinson |
US7763588B2 (en) * | 2003-06-13 | 2010-07-27 | The Salk Institute For Biological Studies | Method for increasing cognitive function and neurogenesis |
WO2005025561A1 (en) * | 2003-09-04 | 2005-03-24 | Synergia Pharma, Inc. | Compositions and methods for orthostatic intolerance |
CA2537765A1 (en) * | 2003-09-04 | 2005-03-17 | Board Of Regents, The University Of Texas System | Methods and compositions for the prevention and treatment of genitourinary disorders, including pre-term labor and leiomyomas |
EP1588704A1 (en) | 2004-04-22 | 2005-10-26 | Newron Pharmaceuticals S.p.A. | Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders |
WO2006042249A2 (en) * | 2004-10-08 | 2006-04-20 | Neuromolecular Pharmaceuticals, Inc. | Methods and compositions for treating migraine pain |
US7619007B2 (en) | 2004-11-23 | 2009-11-17 | Adamas Pharmaceuticals, Inc. | Method and composition for administering an NMDA receptor antagonist to a subject |
JP2008526923A (ja) * | 2005-01-13 | 2008-07-24 | ノイロサーチ アクティーゼルスカブ | 新規8−置換8−アザ−ビシクロ[3.2.1]オクタン誘導体及びモノアミン神経伝達物質再取り込み阻害剤としてのそれらの使用 |
DK1874282T3 (da) * | 2005-04-06 | 2010-10-25 | Adamas Pharmaceuticals Inc | Fremgangsmåder og præparater til behandling af CNS lidelser |
US20070118044A1 (en) * | 2005-07-18 | 2007-05-24 | Mega Elektroniikka Oy | Method and device for identifying; measuring and analyzing abnormal neurological responses |
EP1870097A1 (en) * | 2006-06-15 | 2007-12-26 | Newron Pharmaceuticals S.p.A. | Alpha-aminoamide derivatives useful in the treatment of cognitive disorders |
RU2324492C1 (ru) * | 2006-12-04 | 2008-05-20 | Общество с ограниченной ответственностью "Березовый мир" | Средство для профилактики и лечения болезни паркинсона |
NZ582917A (en) | 2007-06-29 | 2013-01-25 | Univ Emory | Nmda receptor antagonists for neuroprotection |
CN102105169B (zh) * | 2008-06-06 | 2014-09-10 | 图必制药公司 | 用于治疗帕金森病的药物组合物 |
US8648198B2 (en) | 2011-01-19 | 2014-02-11 | Cold Spring Harbor Laboratory | Phenylethanolamine-based NMDA receptor antagonists |
WO2013156614A1 (en) * | 2012-04-20 | 2013-10-24 | Ucb Pharma S.A. | Methods for treating parkinson's disease |
MX2016011837A (es) | 2014-03-13 | 2017-04-27 | Neuroderm Ltd | Composiciones de inhibidores de la dopa decarboxilasa. |
US10258585B2 (en) | 2014-03-13 | 2019-04-16 | Neuroderm, Ltd. | DOPA decarboxylase inhibitor compositions |
US11844754B2 (en) | 2020-11-17 | 2023-12-19 | Neuroderm, Ltd. | Methods for treatment of Parkinson's disease |
US11331293B1 (en) | 2020-11-17 | 2022-05-17 | Neuroderm, Ltd. | Method for treatment of Parkinson's disease |
US11213502B1 (en) | 2020-11-17 | 2022-01-04 | Neuroderm, Ltd. | Method for treatment of parkinson's disease |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5272160A (en) | 1989-05-17 | 1993-12-21 | Pfizer Inc | 2-piperidino-1-alkanol derivatives as antiischemic agents |
WO1991012005A1 (en) | 1990-02-06 | 1991-08-22 | Pfizer Inc. | Neuroprotective 3-piperidino-4-hydroxychroman derivatives and analogs |
CZ390792A3 (en) | 1991-04-18 | 1994-04-13 | Pfizer | Precursors of medicaments based on esters of phenolic 2-piperidino-1-alkanols, process of their preparation, intermediates and use |
DE4118740A1 (de) | 1991-06-05 | 1992-12-10 | Schering Ag | Neue kombinationspraeparate zur behandlung des morbus parkinson |
-
1995
- 1995-05-26 RU RU96109832/14A patent/RU2176145C2/ru not_active IP Right Cessation
- 1995-05-26 EP EP95918111A patent/EP0828513B1/en not_active Expired - Lifetime
- 1995-05-26 CA CA002219911A patent/CA2219911C/en not_active Expired - Fee Related
- 1995-05-26 WO PCT/IB1995/000398 patent/WO1996037226A2/en active IP Right Grant
- 1995-05-26 AT AT95918111T patent/ATE258067T1/de not_active IP Right Cessation
- 1995-05-26 US US08/930,599 patent/US6258827B1/en not_active Expired - Fee Related
- 1995-05-26 PT PT95918111T patent/PT828513E/pt unknown
- 1995-05-26 JP JP8535520A patent/JPH11505828A/ja not_active Ceased
- 1995-05-26 DE DE69532482T patent/DE69532482T2/de not_active Expired - Fee Related
- 1995-05-26 ES ES95918111T patent/ES2211904T3/es not_active Expired - Lifetime
- 1995-05-26 MX MX9709112A patent/MX9709112A/es not_active IP Right Cessation
- 1995-05-26 DK DK95918111T patent/DK0828513T3/da active
-
1996
- 1996-04-30 TW TW085105153A patent/TW470740B/zh not_active IP Right Cessation
- 1996-05-20 IL IL11832896A patent/IL118328A/en not_active IP Right Cessation
- 1996-05-23 CO CO96026135A patent/CO4700422A1/es unknown
- 1996-05-24 TR TR96/00436A patent/TR199600436A2/xx unknown
- 1996-05-24 CN CN96107556A patent/CN1159325A/zh active Pending
- 1996-05-24 SG SG1996009888A patent/SG45479A1/en unknown
- 1996-05-24 PL PL96314413A patent/PL314413A1/xx unknown
- 1996-05-24 NO NO962130A patent/NO962130L/no unknown
- 1996-05-24 AU AU54519/96A patent/AU696258B2/en not_active Ceased
- 1996-05-24 HU HU9601419A patent/HUP9601419A3/hu unknown
- 1996-05-24 NZ NZ286656A patent/NZ286656A/en unknown
- 1996-05-27 BR BR9602485A patent/BR9602485A/pt not_active Application Discontinuation
- 1996-05-27 CZ CZ961524A patent/CZ283979B6/cs not_active IP Right Cessation
-
1997
- 1997-11-25 FI FI974323A patent/FI974323A/fi not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX9709112A (es) | Combinacion para el tratamiento de parkinsonismo que contienen antagonistas selectivos de n-metil-d-aspartato. | |
DE60134453D1 (de) | Pharmazeutische Zusammensetzungen zur Behandlung von ZNS und anderen Krankheiten | |
DE60216830D1 (de) | Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen | |
KR100521829B1 (en) | Compositions and Methods for the Treatment of Alzheimer's Disease, Central Nervous System Injury, and Inflammatory Diseases | |
ATE302194T1 (de) | Metabotrope glutamatrezeptorantagonisten zur behandlung von krankheiten des zentralen nervensystems | |
EP0900568A3 (en) | AMPA antagonists for the treatment of dyskinesias associated with dopamine agonist therapy | |
ATE230989T1 (de) | Anabasein derivate zur behandlung von degenerativen erkrankungen des nervensystems | |
NZ329627A (en) | 8-Heterocyclically substituted 1,3,8-triaza-spiro[4.5]decan-4-ones | |
AUPP674898A0 (en) | A method of treatment | |
WO1999048489A3 (en) | Melatonin for delaying the onset of alzheimer's disease and for treating or delaying the onset of other amyloidosis-related diseases/disorders | |
MY118944A (en) | Synergistic treatment for parkinsonism | |
PH27352A (en) | 4-Benzyl-5-phenyl-2,4-dihydro-3h-1,2,4-triazol-3-ones and their use as anticonvulsants | |
DE69926794D1 (de) | Ponazuril zur behandlung von durch coccidia neurologischen und "abortigenic" verursachten erkrankungen | |
EP0900567A3 (en) | Quinazoline-4-one AMPA antagonists for the treatment of dyskinesias associated with dopamine agonist therapy | |
WO1994024279A3 (en) | Agents for the prevention and treatment of huntington's disease and other neurological disorders | |
Gowri Thilagam et al. | Anti convulsant property of Melatonin in Electro and Chemo induced Convulsions in Rats. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration | ||
MM | Annulment or lapse due to non-payment of fees |